Chronic kidney disease is associated with increased risk of sudden cardiac death among patients with coronary artery disease  by Pun, Patrick H. et al.
Chronic kidney disease is associated with increased
risk of sudden cardiac death among patients with
coronary artery disease
Patrick H. Pun1,4, Thomas R. Smarz2,4, Emily F. Honeycutt3, Linda K. Shaw3, Sana M. Al-Khatib1 and
John P. Middleton1
1Department of Medicine, Duke University Medical Center, Durham, North Carolina, USA; 2Metrolina Nephrology Associates, Charlotte,
North Carolina, USA and 3Duke Clinical Research Institute, Durham, North Carolina, USA
Sudden cardiac death is the most common cause of mortality
among patients with end-stage kidney disease maintained
on hemodialysis. To examine whether this increased risk is
also seen with less advanced kidney disease, we studied the
relationship between glomerular filtration rate and risk of
sudden cardiac death in patients with moderate kidney
disease and known coronary artery disease. This
retrospective longitudinal study encompassed 19,440
consecutive patients who underwent cardiac catheterization
at a single academic institution. There were 522 adjudicated
sudden cardiac death events, yielding an overall rate of 4.6
events per 1000 patient years. This figure reflected rates of
3.8 events in 14,652 patients with estimated glomerular
filtration rates (eGFR) X60 (stage 2 CKD or better) and 7.9
events in 4788 patients with glomerular filtration rates o60
(stage 3–5 CKD), all normalized to 1000 patient-years. After
adjusting for differences in known cardiac risk factors and
other covariates in a multivariate Cox proportional hazards
model, the eGFR was independently associated with sudden
cardiac death (hazard ratio (HR)¼ 1.11 per 10ml/min decline
in the eGFR). Our analysis found that reductions in the eGFR
in CKD stages 3–5 are associated with a progressive increase
in risk of sudden cardiac death in patients with coronary
artery disease. Additional studies are needed to better
characterize the mechanisms by which reduced kidney
function increases this risk.
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Chronic kidney disease (CKD) affects more than 20 million
people in the United States, roughly 13% of the population,
and 485,000 patients have end-stage renal disease (ESRD)
requiring renal replacement therapy.1 Patients with all stages
of CKD have a high prevalence of cardiovascular morbidity,
but the risk of cardiovascular mortality is highest in patients
with ESRD whose risk is 30 times greater than that of the
general population.2–4 Among patients with ESRD, the
leading cause of cardiovascular mortality is sudden cardiac
death (SCD), defined as death resulting from the sudden,
unexpected cessation of cardiac activity with hemodynamic
collapse.2,5,6 Although the risk of SCD among ESRD patients
is well documented, it is unclear whether this risk results
primarily from the dialysis procedure or from a diminished
glomerular filtration rate (GFR) independent of other known
SCD risk factors.
In certain populations, a decreased GFR seems to be
associated with an increased risk of SCD. In patients
presenting with an acute myocardial infarction complicated
by left ventricular dysfunction and/or heart failure who were
enrolled in the VALsartan In Acute myocardial iNfarcTion
(VALIANT) trial, a diminished GFR was independently
associated with an increased risk of cardiovascular death.4
Resuscitation from cardiac arrest was also included as an
outcome in this study, but the number of resuscitation events
was too small to allow a clear characterization of the
relationship between these events and CKD. In a subgroup
analysis of patients with advanced heart failure and reduced
left ventricular ejection fraction enrolled in the Multicenter
Automatic Defibrillator Implantation Trial-II (MADIT-II),
increased SCD risk was observed in subjects with lower
GFR.7,8 More recently, in a cohort of postmenopausal women
with coronary heart disease, declining GFR was found to be
an independent predictor of SCD.9 Even though the
mechanisms that confer this risk are not yet defined, these
observations made in restricted populations suggest that a
diminished GFR may be predictive of SCD.
We conducted this retrospective study to examine the risk
of SCD in a large cohort of patients with CKD. We used the
Duke Databank for Cardiovascular Disease (DDCD), a large
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database of patients undergoing a cardiac procedure at Duke
Hospital that provides long-term follow-up data on patients
with documented coronary artery disease (CAD). We
hypothesized that decrements of GFR are associated with
an increased risk of SCD and that this association is
independent of known cardiac risk factors, including severity
of preexisting cardiac disease.
RESULTS
From 1 January 1995 through 30 June 2006, 69,624 cardiac
catheterizations on 51,694 patients were recorded in DDCD.
After excluding patients not eligible for this analysis, 19,440
patients were included in the study cohort (Figure 1). Table 1
depicts the baseline characteristics of patients by estimated
GFR (eGFR). The median age of patients in the cohort was 63
years, 66% were male, 77% were Caucasian, 65% were
hypertensive, 29% were diabetic, and 59% had hyperlipide-
mia. A total of 4788 (24.6%) patients had an eGFRo60 ml/min
at the time of cardiac catheterization. A total of 249 (1.3%)
patients were receiving dialysis therapy at the time of cardiac
catheterization.
In the 12-year study period, we were able to ascertain vital
status and to determine cause of death for 97.1% of all study
participants. The median follow-up time was 5.5 years
(interquartile range 3.0–8.8). There were 522 SCD events with
an SCD rate of 4.6 per 1000 patient-years. For patients with
an eGFRX60 ml/min, the SCD rate was 3.8 per 1000 patient-
years; for patients with an eGFR 15–59 ml/min, it was 7.3 per
1000 patient-years. For those with eGFRo15 but not yet on
dialysis at baseline, the rate increased to 12.6 per 1000
patient-years, and the rate nearly doubled for patients on
dialysis to 24.2 per 1000 patient years (Figure 2). Of these
events, 274 events were classified as witnessed sudden death,
60 were deaths after resuscitation, and 188 were unobserved
deaths. The unadjusted hazard ratios for SCD are presented
in Table 2. The risk of SCD was significantly higher for
patients with an eGFR o60 ml/min compared with those
with an eGFR X60 ml/min (Po0.0001). The relationship
between baseline eGFR and SCD risk is graphically depicted
in Figure 3.
The variables that were found to be significantly associated
with SCD are listed in Table 3. Baseline eGFR was strongly
associated with SCD, with an adjusted hazard ratio of 1.11
per 10 ml/min decrement in eGFR (95% CI: 1.06, 1.17), and
accounted forB11% of the predictive value of the model. In
the adjusted model, eGFR had an independent and strong
association with SCD roughly equivalent to the association
observed with treatment of CAD with percutaneous inter-
vention and stronger than associations observed with severity
of CAD, congestive heart failure (CHF), and diabetes. Upon
excluding patients with unobserved death, eGFR remained
independently associated with the end point of witnessed
SCD, with an adjusted hazard ratio of 1.16 (95% CI: 1.09,
1.23) for each 10 ml/min reduction in eGFR.
DISCUSSION
This study shows that CKD is strongly and independently
associated with SCD in patients known to have CAD. After
accounting for case-mix factors, medications, clinical vari-
ables, and known cardiac risk factors, each 10 ml/min
decrement in eGFR the risk for SCD increased by 11%.
Furthermore, a 10 ml/min decrement in eGFR had a stronger
association with SCD than all other variables examined
except for treatment of CAD with coronary artery bypass
grafting (CABG). Even when SCD was defined strictly as
witnessed SCD events, the risk associated with decreased
eGFR persisted.
In the 19,440 patients included in this study, we
characterized 522 events as SCD over a 12-year interval.
The event rate at 1-year post-catheterization was 0.7%. This
is similar to the SCD annual event rates estimated for the
general population (0.2%), for those patients with known
cardiovascular risk factors (0.5%), and in women followed in
the HERS trial (0.5–1.7%).9–11 This study extends initial
observations that were made in smaller restricted populations
to a larger, more diverse cohort. Our study provides more
evidence that patients with CKD have an increased risk of
SCD and that this risk begins as early as stage 3 CKD, or
eGFR o60 ml/min.
Why patients with CKD are at an increased risk for SCD is
largely speculative, but it is likely mediated, at least in part, by
structural changes in the heart caused by CKD. The
prevalence of left ventricular hypertrophy is particularly high
among patients with CKD.12 ‘Uremic cardiomyopathy,’ a
condition seen in patients with advanced CKD, includes left
ventricular hypertrophy, dilation, and systolic dysfunc-
tion.13–15 Other ultrastructural abnormalities have been
69,624 Cardiac catherizations 1995–2006
19,440 patients included for analysis
Exclusions
1809 Missing serum creatinine
724 with implantable cardioverter defibrillator
251 with shock (systolic BP <80)
26,107 without significant CAD
17,930 repeat catherization in same patient
2767 on antiarrhythmic medication
45 Died < 5 days post catheterization,
     without revascularization
28 hypertrophic obstructive cardiomyopathy
49 Pericardial disease
89 Severe liver disease
99 incomplete follow-up data
133 catherization for congenital heart disease
153 catherization for cardiac transplantation
Figure 1 | Study flow diagram illustrating cohort entry criteria
and exclusions. A total of 19,440 patients were included from
among all patients undergoing cardiac catheterization over the
12-year study period after the exclusions listed above. BP, blood
pressure; CAD, coronary artery disease.
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observed in advanced CKD patients. A decreased GFR has
been proposed to cause endocardial as well as diffuse
myocardial fibrosis that could enhance the risk of life-
threatening ventricular arrhythmias and SCD.15 These cardiac
morphological changes could be the primary mediators of the
kidney-associated risk of SCD.12–14 Alternatively, patients with
CKD tend to be less likely to have cardiac interventions,16 and
this practice may play a role in the observed excess SCD risk.
In this study, we found that the relationship between GFR and
risk of SCD persisted even after accounting for medication use
at the time of catheterization and revascularization proce-
dures after catheterization.
The risk of SCD in patients with CKD could also be
mediated by dynamic metabolic and physiological changes
that are known to be present. These changes include, but are
not limited to (1) the metabolic derangements of a uremic
milieu such as hyperkalemia, metabolic acidosis, anemia, and
secondary hyperparathyroidism;17,18 (2) electrophysiological
abnormalities such as triggered automaticity and ventricular
repolarization abnormalities;19 (3) transient functional
changes that result from volume overload; and (4) a
generalized microinflammatory state characterized by hy-
poalbuminemia, elevated homocysteine, and higher levels of
serum inflammatory markers, which may contribute to
Table 1 | Baseline characteristics of the study cohort
GFR X60ml/min GFR 15–59ml/min GFR o15ml/min Total P-value*
Number 14,652 4364 424 19,440
Median age (IQR) 60 (52, 69) 71 (64, 77) 61 (52, 69) 63 (54, 72) o0.001a,c
% Male 70.45 51.40 51.42 65.76 o0.001a,b
% Caucasian 77.19 79.87 40.77 76.98 o0.001a,b,c
Median systolic pressure (IQR) 141 (124, 160) 149 (130, 170) 157 (136, 175) 143 (126, 162) o0.001a,b,c
Median diastolic pressure (IQR) 79 (70, 88) 78 (68, 87) 81 (70, 93) 79 (69, 88) o0.001a,b,c
Median pulse (IQR) 69 (60, 80) 70 (61, 80) 75 (67, 85) 70 (61, 80) o0.001a,b,c
% Hypertensive 61.79 75.53 89.39 65.47 o0.001a,b,c
% Diabetic 26.49 35.70 62.97 29.36 o0.001a,b,c
% Hyperlipidemia 58.65 59.46 51.89 58.68 0.010b,c
% Tobacco use 60.95 48.21 35.38 57.53 o0.001a,b,c
% History of congestive heart failure 16.86 33.99 41.45 21.26 o0.001a,b,c
New York Heart Association Class o0.001a,b
None 85.83 69.54 62.95 81.73
I 2.35 4.97 6.99 3.03
II 4.33 6.74 5.96 4.90
III 4.62 11.69 13.21 6.37
IV 2.86 7.06 10.88 3.97
Median left ventricular ejection fraction % (IQR) 57 (47, 65) 54 (41, 63) 52 (40, 60) 56 (45, 64) o0.001a,b
% Peripheral vascular disease 9.15 15.74 19.34 10.85 o0.001a,b
% Cerebrovascular disease 8.77 16.43 15.09 10.63 o0.001a,b
% History of myocardial infarction 46.18 44.39 37.50 45.59 o0.001b,c
% Atrial fibrillation during hospitalization 5.80 10.63 5.66 6.88 o0.001a,c
% Previous coronary artery bypass grafting 17.48 24.54 13.92 18.99 o0.001a,c
% Previous percutaneous coronary intervention 11.84 11.55 6.60 11.66 0.004b,c
Number of diseased vessels o0.001a,b
1 47.69 35.70 31.84 44.66
2 25.06 24.77 30.42 25.11
3 27.25 39.53 37.74 30.23
% On dialysis 0 0 58.73 1.28 o0.001b,c
Median years to death or last known alive (IQR) 6.1 (3.2, 9.1) 4.2 (2.0, 7.4) 2.1 (1.0, 4.2) 5.5 (3.0, 8.8) o0.001a,b,c
In-hospital medications
% Aspirin 90.01 90.01 82.31 89.84 o0.001b,c
% Statins 53.41 53.32 42.92 53.16 o0.001b,c
% b-Blockers 78.28 77.41 77.83 78.07 0.472
% ACEI/ARB 55.11 57.86 51.42 55.64 0.001a
% Diuretics 31.78 53.69 32.08 36.71 o0.001a,c
% K-sparing diuretics 1.37 3.41 0.94 1.82 o0.001a,c
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; GFR, glomerular filtration rate; IQR, interquartile range.
*P-value o0.01 for pairwise comparisons as follows:
aGFR X60 vs GFR 15–59;
bGFR X60 vs GFRo15; and
cGFR=15–59 vs GFRo15.
Data reported as percentages or medians with IQR in parentheses. P-values reported using the Kruskal–Wallis test and Wilcoxon rank-sum test for continuous variables and
the Pearson w2-test for categorical variables.
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arrhythmogenesis.20 Once CKD progresses to ESRD, hemo-
dynamic rigors and biochemical shifts associated with
conventional renal replacement therapies such as hemodia-
lysis could trigger additional SCDs. Indeed, this study
suggests that an additive risk is conferred by dialytic therapy
because the SCD rate for dialysis patients far exceeded the
SCD rate of patients with an eGFR o15 but not yet on
dialysis (Figure 2). However, this study clearly indicates that
the risk of sudden death is high in CKD patients long before
they ever develop ESRD.
This study has several important strengths. The cohort of
patients is large, and patients are well characterized. The
demographics of the study group, namely 66% males, 23%
non-Caucasian, 29% diabetic, resemble those of the CKD
population in the United States.21 Unlike other reports, this
study examines associations among earlier stages of CKD. In
addition, the causes of death were adjudicated by two blinded
clinicians based on first-hand interviews with observers and
medical chart reviews.
Our study has several limitations. First, only patients with
known, significant CAD were included; hence, we cannot
completely exclude the possibility that a different relationship
may exist in among patients without significant CAD.
Second, we used serum creatinine at the time of catheteriza-
tion and the Modification of Diet in Renal Disease (MDRD)
equation to estimate GFR. Given the often progressive nature
of CKD, some of the SCD events may have occurred at later
stages of CKD or during renal replacement therapy. In
addition, estimating equations using serum creatinine are
known to be imperfect, and the study population examined
here differs substantially from the original MDRD study
population of nonhospitalized, mostly non-diabetic, Cauca-
sian patients. Therefore, we cannot exclude the possibility
that patients were improperly categorized due to errors in
GFR estimates.22 In particular, the MDRD equation is known
to be less accurate in populations with normal or near-
normal GFR.23 Third, because our cohort included only
patients who underwent a cardiac catheterization, patients
with more advanced CKD were underrepresented in the
database most likely because of concerns regarding the effect
of contrast dye on renal function. Fourth, although our
analysis accounted for important post-catheterization thera-
pies such as revascularization procedures, we did not
ascertain other therapies (such as medications) that may
have been instituted later and may have affected SCD risk.
However, the goal of this analysis was to address the risk of
SCD among patients with baseline CKD, and future studies
should explore how this risk relates to the use of available
medical therapies. Finally, as with all retrospective studies,
unforeseen and unmeasured confounders could have resulted
in bias. In particular, 24% of the study cohort had missing
data on ejection fraction, an important predictor of SCD risk,
which is routinely measured during catheterization by
Table 2 | Unadjusted hazard ratios for SCD by GFR
Estimated
GFRml/min N Hazard ratio
95% Confidence
interval
X60 14,652 Reference Reference
15–59 4364 1.88 1.56, 2.28
o15 424 4.68 3.06, 7.17





















Figure 3 |Unadjusted SCD risk expressed as logarithm of the
hazard ratio across the spectrum of eGFR. Red lines illustrate
95% confidence intervals. eGFR is inversely and linearly related to
increased SCD risk. There does not appear to be an increasing
benefit for SCD-free survival above GFR values over 90ml/min/




























Figure 2 |Rates of SCD by the baseline eGFR category: Rates
shown as events per 1000 patient-years and were as follows: eGFR
X60ml/min, 3.8 (95% CI: 0, 8); eGFR 15–59ml/min, 7.3 (95% CI: 2,
13); eGFR o15 not on dialysis, 12.6 (95% CI: 5, 20); and dialysis,
24.2 (95% CI: 14, 34). For all subsequent analyses, dialysis and
non-dialysis patients with eGFR o15 were combined into a
single group (eGFR o15).
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ventriculogram, but was likely not performed in advanced
CKD patients because of concerns for contrast nephropathy.
Nevertheless, after supplementing missing data with ejection
fraction reported from concurrent echocardiograms, the
median ejection fraction did not differ by more than 5%
between any group, which is within the expected inter-
observer variability for ejection fraction measured by
echocardiogram and therefore unlikely to have significantly
affected the study results.24 However, we had detailed
information regarding other important covariates including
severity of CAD, clinical diagnosis of CHF, and early post-
catheterization revascularization, and we excluded patients
with major potential confounders such as the use of an
implantable automated defibrillator and antiarrhythmic
medications.
We conclude from this study that diminished kidney
function carries a strong, independent, and incremental risk
for SCD in patients with underlying CAD. Efforts to reduce
progression of kidney disease should be prioritized in order
to reduce the accompanying risk of cardiovascular death.
Studies are required to better characterize the mechanisms
through which CKD increases the risk of SCD.
MATERIALS AND METHODS
Description of data source
Patients for this retrospective cohort study were identified using the
DDCD. This database compiles data on the clinical course of all
patients who undergo a cardiac catheterization, an interventional
cardiac procedure, or a coronary artery bypass surgery at Duke
University Medical Center. Patient information that is prospectively
collected by this database includes symptoms at the time of cardiac
procedures, co-morbidities, primary diagnoses, medications, and
cardiac procedure results, including severity of CAD and measures
of left ventricular function.25 In patients with clinically significant
CAD (defined as having at least one vessel with stenosisX75%), the
DDCD routinely collects follow-up data on mortality, cardiovas-
cular events, hospitalizations, and medications using mailed
questionnaires at 6 months, 1 year, and annually thereafter. Patients
who do not respond to the mailed questionnaire are then surveyed
by phone. Patients not successfully contacted through the afore-
mentioned mechanisms have their vital status determined through a
search of the National Death Index (NDI). The institutional human
subjects review committee reviewed and approved the study.
Participants and study design
Our study cohort consisted of consecutive patients with clinically
significant CAD who were enrolled in the database from 1 January
1995 to 30 June 2006. Patients with a serum creatinine measurement
within 30 days preceding the day of catheterization who had
long-term follow-up were included in this analysis. Only patients
with stable serum creatinine undergo elective catheterization,
and patients are maximally hydrated before the procedure according
to the standard of care at our institution. All laboratory testing
was performed at a single institution’s core laboratories. Serum
creatinine was determined using the enzymatic Jaffe´ method.
Patients were excluded from the study cohort if the
cardiac catheterization was performed to evaluate congenital or
pericardial disease, hypertrophic cardiomyopathy, or for
assessment before organ transplantation. As the focus of our
analysis was to study the independent effect of reduced GFR
on SCD risk, we also chose to exclude patients with a prior
history of arrhythmia and those receiving antiarrhythmic therapy
including an implantable cardioverter defibrillator at the time of
catheterization. Other specific exclusion criteria are shown in
Figure 1.
The eGFR at baseline was estimated for all patients using the
modified MDRD equation26 (186 (serum creatinine in mg per
100 ml)1.154 (age in years)0.203 0.742 for females 1.21 for black
race) and the last recorded serum creatinine before cardiac
catheterization. Study patients were allocated to one of three groups
based on the estimated pre-cardiac catheterization eGFR: (1) eGFR
X60, (2) eGFR 15–59, and (3) eGFR o15 or receiving dialysis





interval Wald v2 P-value
CABG treatment 0.41 0.31, 0.56 34.0 o0.001
GFRa (HR per 10ml/min decrease) 1.11 1.06, 1.17 18.0 o0.001
PCI treatment 0.63 0.50, 0.78 17.4 o0.001
History of diabetes 1.49 1.19, 1.87 12.3 o0.001
In-hospital diuretic use 1.55 1.21, 1.98 12.1 o0.001
History of COPD 1.61 1.21, 2.13 10.7 0.001
History of myocardial infarction 1.34 1.11, 1.62 9.1 0.003
In hospital ACEI/ARB use 1.36 1.10, 1.68 8.0 0.005
Number of diseased coronary vessels 1.25 1.06, 1.47 7.0 0.008
Smoking history 1.30 1.06, 1.60 6.3 0.012
History of hyperlipidemia 0.80 0.67, 0.97 5.5 0.019
New York Heart Association Class (HR per 1 increase; classes III and IV combined) 1.10 1.01, 1.20 5.1 0.024
History of peripheral vascular disease 1.31 1.02, 1.66 4.6 0.032
Any valvular heart disease 1.30 1.02, 1.66 4.4 0.036
ACEI/ARB, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart
failure; COPD, chronic obstructive pulmonary disease; eGFR, estimated GFR; GFR, glomerular filtration rate; HR, hazard ratio; PCI, percutaneous intervention; SCD, sudden
cardiac death.
Overall model w2=383.2. All variables listed above included in the adjusted model as well as age, gender, and propensity scores for PCI, CABG, and medical treatment only
after catheterization.
aGFR values above 90 were truncated at 90 to satisfy linearity assumption.
HRs reported using Cox proportional hazards regression modeling. All variables that were significantly associated with SCD are listed in order of influence in the adjusted
model. As illustrated by Wald w2 values, eGFR had an independent and strong association with SCD equivalent to the association between severity of CAD, CHF, and diabetes.
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therapy. For analyses using eGFR as a continuous variable, patients
on dialysis were assigned the median eGFR value of the rest of the
non-dialysis subjects in the GFRo15 group. eGFR was expressed as
ml/min per 1.73 m2.
Primary end point
The primary end point of this analysis is SCD. In patients with
significant CAD, data on cause of death are collected through mailed
questionnaires or during phone surveys of surviving family
members. Cause of death is further verified using available hospital
records, death certificates, and query of the NDI. For this study,
SCD was defined as a composite of the following: (1) sudden death
defined as death from cardiac or unknown causes that occurs
instantaneously or within 60 min of the onset of symptoms; (2)
post-resuscitation death includes patients who meet the criteria for
sudden death and are temporarily resuscitated but subsequently die
more than 60 min from the onset of symptoms leading to the arrest;
and (3) unobserved death is defined as death occurring in patients
last seen alive more than 60 min before the discovery of death and
the circumstances directly leading to the death are unknown. Deaths
coded as SCD on the death certificate or the NDI without other
supporting evidence regarding the circumstances of death were not
considered SCD in this study. Two independent reviewers
adjudicated all deaths.
Statistical analysis
Baseline characteristics were compared using the Kruskal–Wallis test
and Wilcoxon rank-sum test for continuous variables and the
Pearson w2-test for categorical variables. The log-rank test was used
to compare unadjusted SCD rates across eGFR groups. Patients were
censored for any of the following: alive at the end of observation
period (28 February 2008), lost to follow-up, and death not due to
SCD. Unadjusted and adjusted results were examined using Cox
proportional hazards modeling.27 Unadjusted hazard ratios for SCD
were calculated using the group with an eGFR X60 ml/min as the
reference group. Model variables were selected according to three
criteria: statistical strength of association with the outcome
(unadjusted association Po0.1), prior studies, and clinical insight
regarding factors likely to contribute to adverse outcomes.
Candidate variables included age, race, gender, severity of CHF,
severity of CAD, diabetes mellitus, history of smoking, peripheral
vascular disease, cerebrovascular disease, history of hypertension,
valvular heart disease, history of prior revascularization with CABG
or percutaneous intervention, body mass index, blood pressure
and pulse at the time of catheterization, history of myocardial
infarction, and in-hospital medications. The regression assumption
of linearity in the Cox proportional hazards model was explicitly
tested for both continuous and ordinal variables, and transforma-
tions were made as appropriate. Variables were added in a forward
stepwise approach. We conducted a sensitivity analysis that only
included witnessed sudden death as the end point (excluding
unobserved death).
Patients were assigned to percutaneous intervention or CABG
treatment groups, respectively, if they underwent these procedures
within 30 days of the initial cardiac catheterization. Patients who
did not undergo revascularization within 30 days were designated
in the medical group. Patients who died within 5 days of the
initial catheterization without revascularization (the median
time to percutaneous intervention or CABG at Duke) were excluded
from the analysis to avoid attributing early deaths to the
medically treated cohort. In addition, because revascularization
was not randomly assigned, we adjusted for propensity to select
revascularization as a treatment option. From this analysis, we
created a ‘propensity score’ for each patient representing that
patient’s probability of selection for the treatment being modeled.28
Clinical information generally available to a clinician were
used as candidate variables in developing the propensity model.
These propensity scores were used as covariates in the final survival
model.
All tests were two-sided and were carried out using SAS 8.2 (SAS
Institute, Cary, NC, USA). The results were declared significant at a
P-value of o0.05.
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